Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228095 | 1.00 | QDPR (0.57) | QDPRALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL17197300 | 0.91 | QDPR (0.69) | QDPRALDH1A1LMNASIRT6NAMPT | |
| SCHEMBL28435175 | 0.88 | QDPR (0.46) | QDPRALDH1A1LMNAKDM4EALOX15 | |
| SCHEMBL20516333 | 0.88 | QDPR (0.54) | QDPRALDH1A1LMNASIRT6NAMPT | |
| SCHEMBL17197280 | 0.88 | QDPR (0.54) | QDPRALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL30957987 | 0.86 | QDPR (0.52) | QDPRALDH1A1LMNANAMPTMAPT | |
| SCHEMBL17197370 | 0.86 | QDPR (0.52) | QDPRALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL520721 | 0.86 | QDPR (0.52) | QDPRALDH1A1LMNANAMPTMAPT | |
| SCHEMBL17197282 | 0.85 | QDPR (0.51) | QDPRALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL17398277 | 0.85 | QDPR (0.47) | QDPRALDH1A1LMNAKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-8975250-B2 | 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases | SANOFI (FR) | 2015-03-10 | — | — | US | disclosed |
| EP-2675794-A1 | SELECTIVE FAK INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2013-12-25 | — | — | EP | disclosed |
| EP-2521726-B1 | 5-OXO-5,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CAMKII KINASES INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| EP-2521726-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| WO-2012110774-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2012-08-23 | — | — | WO | disclosed |
| WO-2011086306-A9 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011086306-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | QDPR 2799/4885ALDH1A1 2548/4885LMNA 2914/4885 |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | QDPR 3114/4885ALDH1A1 3249/4885LMNA 2617/4885 |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CAMKK1, CAMKK2, CAMK1 | QDPR 385/4885ALDH1A1 2432/4885LMNA 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.